These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 11364534)

  • 1. Hydroxyurea.
    Bowers M
    BETA; 1997 Mar; ():9-11. PubMed ID: 11364534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New data intensifies interest in hydroxyurea.
    Santiago LG
    GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea, a potential new anti-HIV agent.
    Torres G
    GMHC Treat Issues; 1995 Jan; 9(1):7-9. PubMed ID: 11367381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
    Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
    Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.
    Szekeres T; Fritzer-Szekeres M; Elford HL
    Crit Rev Clin Lab Sci; 1997; 34(6):503-28. PubMed ID: 9439883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F; Lisziewicz J
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea for HIV?
    Treat Rev; 1998; (No 28):10-2. PubMed ID: 11365419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
    Sumpter LR; Inayat MS; Yost EE; Duvall W; Hagan E; Mayhew CN; Elford HL; Gallicchio VS
    Antiviral Res; 2004 Jun; 62(3):111-20. PubMed ID: 15130534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea: mechanisms of HIV-1 inhibition.
    Lori F; Lisziewicz J
    Antivir Ther; 1998; 3 Suppl 4():25-33. PubMed ID: 10723506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
    Gao WY; Zhou BS; Johns DG; Mitsuya H; Yen Y
    Biochem Pharmacol; 1998 Jul; 56(1):105-12. PubMed ID: 9698094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea--ever more fascinating.
    Horn T
    Notes Undergr; 1998; (No 37):1-3, 9. PubMed ID: 11365816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea toxicity in human immunodeficiency virus-positive patients.
    Goodrich J; Khardori N
    Clin Infect Dis; 1999 Sep; 29(3):692-3. PubMed ID: 10530476
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.
    Seminari E; Lisziewicz J; Tinelli C; Foli A; Lori F; Maserati R
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):514-8. PubMed ID: 10543320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity.
    Mayhew CN; Phillips JD; Greenberg RN; Birch NJ; Elford HL; Gallicchio VS
    Stem Cells; 1999; 17(6):345-56. PubMed ID: 10606163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea: what it is. New Mexico AIDS InfoNet.
    Newsline People AIDS Coalit N Y; 1998 Mar; ():15. PubMed ID: 11367449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea under study.
    Posit Aware; 1995; ():5. PubMed ID: 11362569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The subcellular location of nucleoside analog phosphorylation is a determinant of synergistic effects of hydroxyurea.
    Zhu C; Johansson M; Karlsson A
    Biochem Biophys Res Commun; 2000 Sep; 276(1):179-82. PubMed ID: 11006103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.